UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”)
published one announcement (the “Public Notice”) to the Australian Securities Exchange on November 16, 2026 titled:
“RAD interim analysis at SNO26 on RAD101 Phase IIb data”
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This Form 6-K, including the exhibits hereto,
is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178)
and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
EXHIBITS
Exhibit
Number |
|
Description |
| 99.1 |
|
RAD interim analysis at SNO26 on RAD101 Phase IIb data |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
RADIOPHARM THERANOSTICS LIMITED |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Amritha Sushil |
| |
|
Amritha Sushil |
| |
|
Company Secretary |
Exhibit 99.1
ASX ANNOUNCEMENT 16 November 2026 |
|
Radiopharm
Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy
at the Society for Neuro-Oncology Annual Meeting
Concordance between 18F-RAD101 PET
and contrast-enhanced MRI (93.5% patient-level agreement); preliminary sensitivity of 85.7% against the reference standard
Favourable safety profile with no serious treatment-emergent
adverse events observed in any of the 32 participants dosed
Final analyses including specificity and complete
diagnostic performance on follow-up planned to be reported in Q1 2027
Recently announced alignment with the U.S. FDA
for a single, multicenter Phase 3 imaging trial evaluating RAD101 in patients with indeterminate brain metastases following radiotherapy
Sydney, Australia– 16 November 2026 – Radiopharm Theranostics
(ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that data from the Phase 2b
imaging study of RAD101 in suspected recurrent brain metastases following radiotherapy were presented at the 31st Society for
Neuro-Oncology (SNO) Annual Meeting, which took place from November 12-15, 2026 in Philadelphia, PA.
“We were honored to present these encouraging interim Phase 2b
results at SNO before an audience of neuro-oncology experts who confront the challenge of distinguishing recurrent disease from treatment-related
effects on a daily basis,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “For clinicians caring
for patients with brain metastases, uncertainty in imaging can have profound implications for treatment decisions, making the need for
more accurate diagnostic tools increasingly urgent. We believe the high concordance observed between RAD101 PET/CT and MRI, together with
encouraging preliminary sensitivity data and a favorable safety profile, further supports RAD101’s potential to address this critical
unmet need. Following our recent alignment with the U.S. FDA on a pivotal Phase 3 imaging study, we remain focused on advancing RAD101
toward a prospective regulatory submission and are actively engaging with potential strategic partners. We look forward to reporting additional
diagnostics accuracy analyses as we continue to build the evidence supporting RAD101’s differentiated value.”
The Phase 2b, open-label, single-dose, single-arm, multicenter imaging
study enrolled 32 participants who had suspected recurrence of previously irradiated brain metastases.
The primary endpoint was concordance with MRI, which had high patient-level
agreement between 18F-RAD101 PET/CT and contrast-enhanced MRI at 93.5% for all-lesion detection. For the secondary endpoint, among the
16 participants evaluable against the reference standard (histopathology or longitudinal MRI follow-up) at the interim analysis, sensitivity
was 85.7%.. No treatment-emergent serious adverse events or clinically significant laboratory or ECG abnormalities were observed. The
company plans on reporting additional diagnostic accuracy data and complete diagnostic follow up in 2027.
RAD101 has received FDA Fast Track Designation to distinguish
between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal
disease. The company has also announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled
RAD101 to support the upcoming Phase 3 registrational trial in the U.S.
In the U.S. alone, there are more than 300,000
patients diagnosed annually with brain metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part,
due to improvements in systemic therapy resulting in a more durable control of the tumors outside of the central nervous system. Contrast-enhanced
Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance
scans to optimise patient care.1
| 1 | A hybrid [18F]fluoropivalate
PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport
| European Journal of Nuclear Medicine and Molecular Imaging |
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT 16 November 2026 |
|
About RAD101
RAD101 is an ¹⁸F-labelled fatty acid analogue that images
FASN-associated fatty acid metabolism in brain metastases. (FASN) is a multi-enzyme protein that catalyses de novo fatty acid synthesis
and is overexpressed in brain metastases from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer
cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College
London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients)
showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may provide non-invasive
prediction of overall survival, warranting larger studies.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated
platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one
Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com
Authorised on behalf of the Radiopharm Theranostics board of directors
by Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889